Semi-Annual Report — FY2026 H1
What TMS Co.,Ltd. reported for the period from 2026-01-01 to 2026-12-31. Filed by ㈱ティムス
Filed 2026-08-14View the original on EDINET
How much it says
64Detailed
What moved here
22named for the first time
Its own wording
31terms
Which filing this is
10/ 10newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the interim accounting period, subject enrollment progressed smoothly in the global Phase II/III ORION trial for TMS-007 (JX10), and enrollment and dosing also began in Japan. For TMS-008, the company developed the design for an early Phase II trial targeting CSA-AKI and prepared the necessary framework. Development of JX-09 was put on hold after completion of Phase I, while pharmacological and efficacy studies for TMS-010 progressed and a clinical-trial plan was developed. The company also recorded R&D expenses and operating and other losses.
Komori's summary of this document, not the document's own words.64Detailed
How much this filing saysA weighted roll-up of 9 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 33 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
54
Typical
88
Very detailed
50
Typical
53
Typical
71
Detailed
53
Typical
55
Typical
73
Detailed
R&D spend2億円Money spent making new things.
Cash left over-3億円Cash from the business, less what went into equipment.
Spent on equipment1百万円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.